Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.66 |
| ▸ | HTR6 | P50406 | 5/20 | 0.65 |
| ▸ | NCF1 | P14598 | 4/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.65 |
| ▸ | HTR3B | O95264 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | HTR5A | P47898 | 1/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359045 | 0.94 | CYP11B1 (0.60) | CYP11B1HTR6NCF1HTR3EHTR3B | |
| SCHEMBL31342013 | 0.83 | CYP11B1 (0.72) | CYP11B1NCF1KDM4EHPGDCYP11B2 | |
| SCHEMBL2420958 | 0.81 | CYP2D6 (0.66) | HTR6NCF1HTR3EHTR3BCYP1A2 | |
| SCHEMBL28033595 | 0.80 | CYP11B1 (0.61) | CYP11B1NCF1HTR3EHTR3BHTR3A | |
| SCHEMBL27856065 | 0.80 | CYP11B1 (0.61) | CYP11B1HTR6HTR1ANFKB1HTR2A | |
| SCHEMBL5820339 | 0.80 | CYP11B1 (0.67) | CYP11B1NCF1KDM4ECYP11B2CDK8 | |
| SCHEMBL3166780 | 0.79 | HTR6 (1.00) | HTR6NCF1HTR3EHTR3BCYP1A2 | |
| SCHEMBL240244 | 0.79 | HTR6 (1.00) | HTR6NCF1HTR3EHTR3BCYP1A2 | |
| SCHEMBL29385724 | 0.79 | HTR6 (1.00) | HTR6NCF1HTR3EHTR3BCYP1A2 | |
| Hydrochloric Acid SCHEMBL25379293 | 0.77 | LMNA (1.00) | HTR6NCF1HTR3EHTR3BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590329-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2005-11-02 | — | — | EP | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-1023296-B1 | 3-SUBSTITUTED PYRIDO 3',4':4,5] THIENO 2,3-D] PYRIMIDINE DERIVATIVES, AND PRODUCTION AND USE OF THE SAME | ABBOTT GMBH & CO KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| EP-0927184-B1 | 3-SUBSTITUTED PYRIDO 4',3':4,5]THIENO 2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2003-10-22 | — | — | EP | disclosed |
| EP-0988306-B1 | 3-SUBSTITUTED 3,4 DIHYDRO-THIENO 2, 3-D]PYRIMIDINE DERIVATIVES AND PRODUCTION AND USE OF THE SAME | ABBOTT GMBH & CO KG (DE) | 2003-07-09 | — | — | EP | disclosed |
| US-6414157-B1 | COMPOUNDS HAVING HIGH AFFINITY FOR 5-HT1B AND 5-HT1C SEROTONIN RECEPTOR; ANTIDEPRESSANTS | ABBOTT LABORATORIES | 2002-07-02 | — | — | US | disclosed |
| US-6387912-B1 | STROKE THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6355647-B1 | INHIBIT THE SEROTONIN REUPTAKE. HYPERPROLACTINEMIA, VASOSPASMS, HYPERTENSION, GASTROINTESTINAL DISORDERS ASSOCIATED WITH MOTILITY AND SECRETION | ABBOTT LABORATORIES | 2002-03-12 | — | — | US | disclosed |
| US-6346622-B1 | ENANTIOMORPHS AND ISOMERS | ABBOTT LABORATORIES | 2002-02-12 | — | — | US | disclosed |
| EP-1023296-A1 | 3-SUBSTITUTED PYRIDO 3',4':4,5] THIENO 2,3-D] PYRIMIDINE DERIVATIVES, AND PRODUCTION AND USE OF THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-02 | — | — | EP | disclosed |
| WO-2000041697-A1 | UTILISATION OF 2-SUBSTITUTED 1,2-BENZISOTHIAZOLE DERIVATIVES AND 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES FOR THE PROPHYLAXIS AND THERAPY OF CEREBRAL ISCHAEMIA | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041695-A1 | UTILIZATION OF PYRIMIDINE DERIVATIVES FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
| EP-1003752-A1 | 3-SUBSTITUTED 3,4,5,7-TETRAHYDRO-PYRROLO3',4':4,5 THIENO2,3-DPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS 5HT ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-31 | — | — | EP | disclosed |
| EP-0988306-A1 | 3-SUBSTITUTED 3,4 DIHYDRO-THIENO 2, 3-D]PYRIMIDINE DERIVATIVES AND PRODUCTION AND USE OF THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999021857-A1 | 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES, METHOD FOR PRODUCING THE SAME, AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999020616-A1 | 2-SUBSTITUTED 1,2-BENZISOTHIAZOLE DERIVATIVES AND THEIR USE AS SEROTONIN ANTAGONISTS (5-HT1A, 5-HT1B AND 5-HT1D) | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999007711-A1 | 3-SUBSTITUTED 3,4,5,7-TETRAHYDRO-PYRROLO3',4':4,5 THIENO2,3-DPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS 5HT ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998056793-A1 | 3-SUBSTITUTED PYRIDO [3',4':4,5] THIENO [2,3-D] PYRIMIDINE DERIVATIVES, AND PRODUCTION AND USE OF THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998056792-A1 | 3-SUBSTITUTED 3,4 DIHYDRO-THIENO[2, 3-D]PYRIMIDINE DERIVATIVES AND PRODUCTION AND USE OF THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | CYP11B1 137/4885HTR6 3115/4885NCF1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.